



March 27, 2020

Dear Novo Nordisk Partner,

We are writing to inform you of some measures Novo Nordisk Canada is taking given the current coronavirus outbreak.

First, Novo Nordisk's key priority is to safeguard the continued supply of our lifesaving medicines to patients. The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.

Secondly, in Canada we will be conducting all group meetings virtually or postponing them; this includes speaker events, CHEs, and learning programs, and advisory boards. We have also advised our employees to suspend all in-person customer interactions as of Monday, March 16 and work from home. Despite these adjustments, we remain committed to continuing to bring new therapies to market that can make a difference for patients.

At Novo Nordisk Canada Inc., we work to change the course of diabetes, hemophilia, growth disorders and other chronic diseases. At this important time, we aim to support our healthcare system to flatten the curve on this outbreak so that there are fewer overall infections and the most acute cases can receive the care they need. We trust you'll understand and support these actions, and we look forward to continuing to collaborate with you.

Sincerely,

Béatrice Clerc
President
Novo Nordisk Canada Inc.

John Burrows
VP, Biopharmaceuticals
Novo Nordisk Canada Inc.